Oculis' Privosegtor Receives FDA Breakthrough Therapy Designation, Targeting $7 Billion Market
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1d ago
0mins
Source: Globenewswire
- Breakthrough Therapy Designation: Oculis' Privosegtor has received FDA Breakthrough Therapy Designation, marking a significant advancement in treating optic neuritis and addressing a substantial $7 billion market gap.
- Clinical Trial Results: In the ACUITY trial, Privosegtor combined with IV steroids led to an average gain of 18 letters in Low Contrast Visual Acuity, demonstrating significant visual improvement that could transform the treatment landscape for optic neuropathies.
- Market Opportunity: The registration plans for Privosegtor include three pivotal trials targeting optic neuritis and non-arteritic anterior ischemic optic neuropathy, aiming to meet the urgent needs of over 30,000 patients in the U.S., thereby driving future growth for the company.
- Strategic Positioning: Oculis' CEO emphasized that the success of Privosegtor will redefine the possibilities of neuroprotective therapies, with 2026 shaping up to be a milestone-rich year for the company's late-stage portfolio.
Analyst Views on OCS
Wall Street analysts forecast OCS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for OCS is 39.50 USD with a low forecast of 29.00 USD and a high forecast of 51.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Analyst Rating
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 20.900
Low
29.00
Averages
39.50
High
51.00
Current: 20.900
Low
29.00
Averages
39.50
High
51.00
About OCS
Oculis Holding AG is a Switzerland-based company primally engaged in biotechnology sector. The Company is focused on the development of eye disease treatment for ophthalmology. It includes OCS-01, based on the OPTIREACH technology, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED) in a form of a single chain antibody fragment; and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and for other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The Company have operations in the USA, Europe and China. Ocullis deliver treatments to patients worldwide.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
